Novartis Seeks Injunction Against Mylan to Stop Gilenya Generic

Novartis Pharmaceuticals Corp. is seeking an injunction to prevent Mylan Pharmaceuticals Inc. from making and selling a generic version of its drug Gilenya.

Mylan notified Novartis in April 2016 that it had submitted an Abbreviated New Drug Application to the Food and Drug Administration for approval to manufacture and sell a generic version of the medication, which treats multiple sclerosis.

Attorneys for Novartis allege in the June 17 complaint that Mylan is infringing its patent for the drug, and they want a declaration to that effect from the U.S. District Court for the District of Delaware. The company asked the ...